Case report demonstrates successful completion of a six-month bedaquiline, pretomanid, and low-dose linezolid regimen in drug-resistant tuberculosis, highlighting alternative dosing viability.
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.
No takes yet. Share an insight, caveat, or question.
Haley et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: